Oxford VR concludes major new investment round to boost pace of product innovation in Virtual Reality psychological therapies

September 20, 2018 | 0 Comments

University of Oxford spinout inks clinical paper in Lancet Psychiatry, appoints CEO and sets up Oxford HQ and London development hub   Oxford VR, a spinout company from the University of Oxford, has raised £3.2m with investors including Oxford Sciences Innovation, University of Oxford, Force Over Mass, RT Capital and GT Healthcare Capital Partners. This new investment round powers the pace of company growth to bring automated immersive, clinically validated Virtual Reality (VR) technologies to market as user-centered treatments for patients with mental health problems. Oxford VR’s first product, an automated VR treatment for height phobia, was tested this year in a…

Read More

Study provides first evidence that psychological therapy can be successfully delivered automatically in virtual reality (VR)

July 12, 2018 | 4 Comments

Today sees the publication in The Lancet Psychiatry of a pioneering clinical trial of automated virtual reality (VR) psychological therapy for fear of heights. Fear of heights is a significant problem for one in five people at some point in their lives, and most never receive treatment. Although VR has been used in the past for phobias, it has always required a therapist to guide the user through the treatment. Now a team led by Professor Daniel Freeman from the University of Oxford’s Department of Psychiatry has developed a VR programme in which psychological therapy is delivered by a computer-generated virtual coach.…

Read More
View previous news